DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
StockStory.org on MSN
Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana stocks trade up, what you need to know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor ...
May 1 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...
Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier†for users, which is currently under FDA and CE mark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results